LynxKite at NVIDIA GTC 2026: AI-Driven Drug Discovery
April 30, 2026At NVIDIA GTC 2026, LynxKite joined BIOPHYTIS - Live Healthier Longer, Nebius, and Accenture to present a fully integrated AI-driven drug discovery approach—combining biological insight, graph-based AI workflows, and scalable GPU infrastructure.
Using Biophytis BIO101 and new generation MAS receptor target as a reference case, our CEO Gyorgy Lajtai and CTO Daniel Darabos, together with Stanislas Veillet (Biophytis) and Dave Malik (Accenture), demonstrated how tightly coupled platform + data + HPC time to market can materially accelerate discovery.
Early-stage discovery timelines moving from ~24 months to 6–8 months are no longer theoretical but becoming operational. Announcements about exciting newly available datasets, methods by NVIDIA and European Bioinformatics Institute (EMBL-EBI) will accelerate things further!